Title: 
Official Title: To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Number of Sections: 2
Source: versions - Introduced in House
Media Type: text/xml

================================================================================

Section 1:
1.Short titleThis Act may be cited as the Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act.

Section 2:
2.Expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation ProgramSection 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—(1)in paragraph (1), by adding at the end the following new subparagraph:(C)Treatment of former orphan drugsIn calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).; and(2)in paragraph (3)(A)—(A)by striking only one rare disease or condition and inserting one or more rare diseases or conditions; and (B)by striking such disease or condition and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act).


================================================================================

Raw Text:
119 HR 946 IH: Optimizing Research Progress Hope And New Cures Act
U.S. House of Representatives
2025-02-04
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



I119th CONGRESS1st SessionH. R. 946IN THE HOUSE OF REPRESENTATIVESFebruary 4, 2025Mr. Joyce of Pennsylvania (for himself, Mr. Davis of North Carolina, Mr. Hern of Oklahoma, Mr. Peters, Mrs. Miller-Meeks, Mr. Keating, Mr. Hudson, Mr. Thanedar, Mr. Bilirakis, and Mr. Gottheimer) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.1.Short titleThis Act may be cited as the Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act.2.Expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation ProgramSection 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—(1)in paragraph (1), by adding at the end the following new subparagraph:(C)Treatment of former orphan drugsIn calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).; and(2)in paragraph (3)(A)—(A)by striking only one rare disease or condition and inserting one or more rare diseases or conditions; and (B)by striking such disease or condition and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act).